Downloads: 135

Files in This Item:
File Description SizeFormat 
66_4_115.pdf685.13 kBAdobe PDFView/Open
Title: 術前化学療法としてゲムシタビン, シスプラチン, S-1併用療法を施行した原発性女子尿道腺癌の1例
Other Titles: Neoajuvant Chemotherapy with Gemcitabine and Cisplatin Plus S-1 for Primary Female Urethral Adenocarcinoma
Authors: 西川, 武友  KAKEN_name
杉野, 友亮  KAKEN_name
大和, 俊介  KAKEN_name
北野, 剛士  KAKEN_name
佐々木, 豪  KAKEN_name
加藤, 学  KAKEN_name
舛井, 覚  KAKEN_name
西川, 晃平  KAKEN_name
吉尾, 裕子  KAKEN_name
神田, 英輝  KAKEN_name
有馬, 公伸  KAKEN_name
杉村, 芳樹  KAKEN_name
内田, 克典  KAKEN_name
Author's alias: Nishikawa, Taketomo
Sugino, Yusuke
Owa, Shunsuke
Kitano, Goshi
Sasaki, Takeshi
Kato, Manabu
Masui, Satoru
Nishikawa, Kohei
Yoshio, Yuko
Kanda, Hideki
Arima, Kiminobu
Sugimura, Yoshiki
Uchida, Katsunori
Keywords: Female urethral tumor
Multimodal therapy
Neoadjuvant chemotherapy
Issue Date: 30-Apr-2020
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 66
Issue: 4
Start page: 115
End page: 119
Abstract: A 67-year-old female presented for evaluation of a left inguinal mass. Contrast-enhanced computed tomography revealed a tumor surrounding the urethra. Magnetic resonance imaging showed that the tumor had invaded the bladder neck on the anterior aspect of the urethra. The serum carbohydrate antigen 19-9 level was elevated. The clinical diagnosis was a primary adenocarcinoma of the female urethra (cT4N2M0). The initial treatment consisted of gemcitabine plus cisplatin (GC) and oral fluoropyrimidine (S-1). A total cysto-urethrectomy with anterior vaginal wall resection, pelvic and inguinal lymphadenectomy, and urinary diversion with ileal conduit formation were performed. The final diagnosis was urethral adenocarcinoma (ypT4ypN2, stage IV). Twelve months post-operatively, there was no evidence of recurrence or distant metastases.
Rights: 許諾条件により本文は2021/05/01に公開
DOI: 10.14989/ActaUrolJap_66_4_115
PubMed ID: 32483945
Appears in Collections:Vol.66 No.4

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.